3,3′-diindolylmethane attenuates colonic inflammation and tumorigenesis in mice

Inflammatory Bowel Diseases

Volumn 15, Issue 8, 2009, Pages 1164-1173

  Kim, Yoon Hee ^a   Kwon, Hyuck Se ^a   Kim, Dae Hwan ^a   Shin, Eun Kyung ^a   Kang, Young Hee ^a   Park, Jung Han Yoon ^a   Shin, Hyun Kyung ^a   Kim, Jin Kyung ^a  

^a Hallym University   (South Korea)

Author keywords

3,3 diindolylmethane; Colon cancer; Inflammatory bowel diseases

Indexed keywords

3 INDOLEMETHANOL; 3,3 ' DIINDOLYLMETHANE; ANTIINFLAMMATORY AGENT; AZOXYMETHANE; CYTOKINE; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOPEROXIDASE; NITRIC OXIDE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; 3,3' DIINDOLYLMETHANE; 3,3'-DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; CARCINOGEN; INDOLE DERIVATIVE; MESSENGER RNA; PEROXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CELL INFILTRATION; COLITIS; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL MOUSE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION; THERAPY EFFECT; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; COLON TUMOR; DISEASE MODEL; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTICARCINOGENIC AGENTS; AZOXYMETHANE; BODY WEIGHT; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; COLITIS; COLONIC NEOPLASMS; DEXTRAN SULFATE; DINOPROSTONE; DISEASE MODELS, ANIMAL; INDOLES; MICE; MICE, INBRED BALB C; NF-KAPPA B; NITRIC OXIDE; PEROXIDASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; WEIGHT LOSS;

EID: 70349498805     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20917     Document Type: Article

References (47)

1. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549.
2. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
3. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79-94.
4. Herszenyi L, Miheller P, Tulassay Z. Carcinogenesis in inflammatory bowel disease. Dig Dis. 2007;25:267-269.
5. Araki Y, Sugihara H, Hattori T. The free radical scavengers edaravone and tempol suppress experimental dextran sulfate sodium-induced colitis in mice. Int J Mol Med. 2006;17:331-334.
6. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology. 2004;113:427-437.
7. Martín AR, Villegas I, Alarcón de la Lastra C. The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice. Inflamm Res. 2005;54:145-151.
8. Halter F, Tarnawski AS, Schmassmann A, et al. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut. 2001;49:443-453.
9. Rojas-Cartagena C, Flores I, Appleyard CB. Role of tumor necrosis factor receptors in an animal model of acute colitis. Cytokine. 2005;32: 85-93.
10. Ito R, Shin-Ya M, Kishida T, et al. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis. 2007;13:1016-1023.
11. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310-1316.
12. Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007;13:629-638.
13. Ananthakrishnan AN, Attila T, Otterson MF, et al. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2007;41:682-688.
14. Giampaolo B, Giuseppe P, Michele B, et al. Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: our experience with a prospective study. World J Gastroenterol. 2006;12: 2201-2204.
15. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 2007;102:2058-2069.
16. Stokkers PC, Hommes DW. New cytokine therapeutics for inflammatory bowel disease. Cytokine. 2004;28:167-173.
17. De Kruif CA, Marsman JW, Venekamp JC, et al. Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro. Chem Biol Interact. 2001;80:303-315.
18. Nachshon-Kedmi M, Yannai S, Haj A, et al. Indole-3-carbinol and 3,3′-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol. 2003;41:745-752.
19. Ali S, Baneriee S, Ahmad A, et al. Apoptosis-inducing effect of erlotinib is potentiated by 3,3′-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther. 2008;7:1708-1719.
20. Hong C, Kim HA, Firestone GL, et al. 3,3′-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis. 2002;23:1297-1305.
21. Cho HJ, Seon MR, Lee YM, et al. 3,3′-Diindolylmethane suppresses the inflammatory response to lipopolysaccharide in murine macrophages. J Nutr. 2008;138:17-23.
22. Copper HS, Murthy SNS, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 66:635-639.
23. Kwon HS, Oh SM, Kim JK. Glabridin, a functional compound of licorice, attenuates colonic inflammation in mice with dextran sulfate sodium-induced colitis. Clin Exp Immunol. 2008;151:165-173.
24. Kim JK, Oh SM, Kwon HS, et al. Anti-inflammatory effect of roasted licorice extracts on lipopolysaccharide-induced inflammatory responses in murine macrophages. Biochem Biophys Res Commun. 2006;345: 1215-1223.
25. Lichtenstein GR. Chemokines and cytokines in inflammatory bowel disease and their application to disease treatment. Curr Opin Gastroenterol. 2000;16:83-88.
26. Danese S. Gasbarrini A. Chemokines in inflammatory bowel disease. J Clin Pathol 2005;58:1025-1027.
27. Keates S, Keates AC, Mizoguchi E, et al. Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis. Am J Physiol. 1997;273:G75-G82.
28. Itzkowitz SH, Yio X. Inflammation and cancer. IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7-17.
29. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118:560-570.
30. Suzuki R, Kohno H, Sugie S, et al. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci. 2004;95:721-727.
31. Sarkar FH, Rahman KM, Li Y. Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol (I3C) treatment of breast cancer cells. J Nutr. 2003;133:2434S-2439S.
32. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005;4:1201-1215.
33. Nachshon-Kedmi M, Fares FA, Yannai S. Therapeutic activity of 3,3′-diindolylmethane on prostate cancer in an in vivo model. Prostate. 2004;61:153-160.
34. Dieleman LA, Ridwan BU, Tennyson GS, et al. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology. 1994;107:1643-1652.
35. Siegmund B, Fantuzzi G, Rieder F, et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol 2001;281:R1264-R1273.
36. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114:385-391.
37. Pullman WE, Elsbury S, Kobayashi M, et al. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology. 1992; 102:529-537.
38. Murthy S, Cooper HS, Yoshitake H, et al. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther. 1999;13:251-260.
39. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182: 1281-1290.
40. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133.
41. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med. 2008;263:591-596.
42. Schottelius AJ, Dinter H. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res. 2006;130:67-87.
43. Rahman KM, Ali S, Aboukameel A, et al. Inactivation of NF-kappaB by 3,3′-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther. 2007; 6:2757-2765.
44. Rahman KW, Sarkar FH. Inhibition of nuclear translocation of nuclear factor-κB contributes to 3,3′-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res. 2005;65:364-371.
45. Kong D, Li Y, Wang Z, et al. Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 2007; 67:3310-3319.
46. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118:285-296.
47. Staub RE, Onisko B, Bjeldanes LF. Fate of 3,3′-diindolylmethane in cultured MCF-7 human breast cancer cells. Chem Res Toxicol. 2006;19: 436-442.